PE20081509A1 - Inhibidores no nucleosidos de transcriptasa inversa - Google Patents

Inhibidores no nucleosidos de transcriptasa inversa

Info

Publication number
PE20081509A1
PE20081509A1 PE2007001776A PE2007001776A PE20081509A1 PE 20081509 A1 PE20081509 A1 PE 20081509A1 PE 2007001776 A PE2007001776 A PE 2007001776A PE 2007001776 A PE2007001776 A PE 2007001776A PE 20081509 A1 PE20081509 A1 PE 20081509A1
Authority
PE
Peru
Prior art keywords
reverse transcriptase
ilamino
benzonitrile
pyrimidin
piperidin
Prior art date
Application number
PE2007001776A
Other languages
English (en)
Inventor
Christine Brotherton-Pleiss
Denis John Kertesz
Minmin Yang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20081509A1 publication Critical patent/PE20081509A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

REFERIDA A UN COMPUESTO DE PIRIMIDINA DE FORMULA (I), DONDE R1 ES CO2-Tert-Bu, CO2Et, FENIL-ALQUILO C1-C3, ENTRE OTROS; R2 ES CN, -CH=CHCN, ALQUILO C1-C3, HALOGENO; R3 ES H, HALOGENO, AMINO, HALOALQUILO C1-C6; R4 ES H O AMINO; R5a Y R5b SON H, ALQUILO C1-C6, ALCOXI C1-C6, HALOGENO; R6a Y R6b SON H O JUNTOS SON ETILENO; X ES NH U O. SON COMPUESTOS PREFERIDOS: 4-[2-(1-BENCIL-PIPERIDIN-4-ILAMINO)-PIRIMIDIN-4-ILOXI]-3,5-DIMETIL-BENZONITRILO, 4-[2-(1-BENCIL-PIPERIDIN-4-ILAMINO)-5-BROMO-PIRIMIDIN-4-IL-OXI]-3,5-DIMETIL-BENZONITRILO, 4-{2-[1-(4-METANOSULFONIL-BENCIL)-PIPERIDIN-4-ILAMINO]PIRIMIDIN-4-ILOXI}-3,5-DIMETIL-BENZONITRILO, ENTRE OTROS. DICHOS COMPUESTOS INHIBEN LA TRANSCRIPTASA INVERSA DEL VIRUS DE INMUNODEFICIENCIA HUMANA (VIH)
PE2007001776A 2006-12-13 2007-12-12 Inhibidores no nucleosidos de transcriptasa inversa PE20081509A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87467306P 2006-12-13 2006-12-13

Publications (1)

Publication Number Publication Date
PE20081509A1 true PE20081509A1 (es) 2008-10-24

Family

ID=39381919

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001776A PE20081509A1 (es) 2006-12-13 2007-12-12 Inhibidores no nucleosidos de transcriptasa inversa

Country Status (17)

Country Link
US (1) US7998969B2 (es)
EP (1) EP2089384B1 (es)
JP (1) JP5415957B2 (es)
KR (1) KR101475091B1 (es)
CN (1) CN101553483B (es)
AR (1) AR064221A1 (es)
AU (1) AU2007332654B2 (es)
BR (1) BRPI0720436A2 (es)
CA (1) CA2671478C (es)
CL (1) CL2007003565A1 (es)
ES (1) ES2550152T3 (es)
IL (1) IL199152A (es)
MX (1) MX2009005881A (es)
PE (1) PE20081509A1 (es)
RU (1) RU2469032C2 (es)
TW (1) TW200833681A (es)
WO (1) WO2008071587A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2718858A1 (en) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Selective synthesis of substituted pyrimidines
UY31714A (es) 2008-03-20 2009-11-10 Boehringer Ingelheim Int Preparación selectiva de pirimidinas sustituidas
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
ES2618889T3 (es) * 2009-01-14 2017-06-22 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para el tratamiento de trastornos inflamatorios
AR076024A1 (es) * 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
US8153790B2 (en) 2009-07-27 2012-04-10 Krizmanic Irena Process for the preparation and purification of etravirine and intermediates thereof
US8933227B2 (en) * 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
JP5539518B2 (ja) * 2009-08-14 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ２−アミノ−５−トリフルオロメチルピリミジン誘導体の位置選択的調製
GR1007010B (el) 2009-10-08 2010-10-07 Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), Ινσουλινοειδη πεπτιδια
CN101723904B (zh) * 2009-11-26 2012-02-08 复旦大学 4-氰基二芳基嘧啶类衍生物及其制备方法和用途
CN103209963A (zh) 2010-07-02 2013-07-17 吉里德科学公司 作为hiv抗病毒化合物的2-喹啉基-乙酸衍生物
AP2013006706A0 (en) * 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
ES2707997T3 (es) 2011-04-21 2019-04-08 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmacéutico
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
CN102382062B (zh) * 2011-08-01 2014-08-13 复旦大学 一种环烷基芳基嘧啶类衍生物及其制备方法和用途
WO2013059572A1 (en) 2011-10-19 2013-04-25 Assia Chemical Industries Ltd. Process for the preparation of etravirine and intermediates in the synthesis thereof
WO2013062028A1 (ja) 2011-10-25 2013-05-02 塩野義製薬株式会社 Ｈｉｖ複製阻害剤
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
JP5911638B2 (ja) 2012-04-20 2016-04-27 ギリアード サイエンシーズ， インコーポレイテッド ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
IN2015DN02814A (es) * 2012-10-26 2015-09-11 Asahi Glass Co Ltd
CN102964295B (zh) * 2012-12-17 2014-08-20 寿光富康制药有限公司 一种2-取代-4-（哌啶基甲基）吡啶的制备方法
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
CN103523533A (zh) * 2013-07-25 2014-01-22 上海董奥机械科技有限公司 一种用于pet空瓶气流输送的装置
CN110066273A (zh) * 2019-06-05 2019-07-30 山东大学 一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
CN110407812B (zh) * 2019-07-31 2020-08-25 武汉工程大学 一种吲唑哌啶嘧啶类衍生物及其制备方法和用途
CN111285859B (zh) * 2020-04-02 2021-07-02 山东大学 一类以hiv-1逆转录酶为靶点的2,4,5-三取代嘧啶类化合物及其制备方法与应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5349068A (en) 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
JP3398152B2 (ja) * 1993-10-12 2003-04-21 ブリストル‐マイヤーズ・スクイブ・ファーマ・カンパニー １ｎ−アルキル−ｎ−アリールピリミジンアミンおよびその誘導体
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
AU4788396A (en) 1995-02-16 1996-09-04 Children's Medical Center Corporation Inhibition of angiogenesis using interleukin-12
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
AU4545500A (en) 1999-04-16 2000-11-02 Lonza A.G. Method for producing 2-(alkylthio)-4-chloropyrimidines
ES2246233T3 (es) 1999-05-04 2006-02-16 Schering Corporation Derivados de piperidina utiles como antagonistas de ccr5.
BR0010304A (pt) 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
KR100548854B1 (ko) 2000-05-26 2006-02-02 화이자 인코포레이티드 Ｃｃｒ5 조절제로서의 트리아졸릴 트로판 유도체
US6620586B2 (en) 2001-02-20 2003-09-16 Applied Gene Technologies, Inc. Methods and compositions for analyzing nucleic acids
US7176199B2 (en) 2001-03-19 2007-02-13 Dainippon Pharmaceutical Co., Ltd. Aryl-substituted alicyclic compound and medical composition comprising the same
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
GB0127547D0 (en) 2001-11-16 2002-01-09 Astrazeneca Ab Chemical compounds
SE0200919D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Chemical compounds
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
US7759336B2 (en) * 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
AR042628A1 (es) 2002-12-20 2005-06-29 Astrazeneca Ab Derivados de piperidina como moduladores del receptor ccr5
WO2005075484A2 (en) 2004-02-10 2005-08-18 F. Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
US20050282793A1 (en) 2004-05-21 2005-12-22 Ralf Wyrwa Steroid prodrugs with androgenic action
PT1761542E (pt) 2004-06-09 2008-03-26 Hoffmann La Roche Derivados de octa-hidro-pirrolo[3,4-c) pirrole e o seu uso com agentes antivirais
MXPA06014637A (es) 2004-06-25 2007-02-12 Amgen Inc Triazoles e indazoles condensados utiles en el tratamiento de enfermedades mediadas por citocinas y otras enfermedades.
AU2005289426A1 (en) * 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1797631B1 (en) 2004-09-28 2009-01-07 Nxp B.V. Current-mode controlled dc-dc converter
AU2005288864B2 (en) 2004-09-30 2012-08-23 Janssen Sciences Ireland Uc HIV inhibiting 5-heterocyclyl pyrimidines
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
MX2007010051A (es) 2005-02-18 2007-09-21 Tibotec Pharm Ltd Derivados de oxido de 2-(4-cianofenilamino)pirimidina que inhiben el virus de inmunodeficiencia humana.
ES2347815T3 (es) 2005-03-04 2010-11-04 Tibotec Pharmaceuticals 2-(4-cianofenil)-6-hidroxilaminopirimidinas inhibidoras de hiv.
CA2612554A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
KR101475091B1 (ko) 2014-12-22
CL2007003565A1 (es) 2008-07-04
CA2671478A1 (en) 2008-06-19
BRPI0720436A2 (pt) 2014-01-07
IL199152A (en) 2015-11-30
JP5415957B2 (ja) 2014-02-12
US20080146595A1 (en) 2008-06-19
KR20090087512A (ko) 2009-08-17
AU2007332654B2 (en) 2013-06-20
AU2007332654A1 (en) 2008-06-19
RU2469032C2 (ru) 2012-12-10
MX2009005881A (es) 2009-06-12
RU2009126624A (ru) 2011-01-20
ES2550152T3 (es) 2015-11-04
CN101553483A (zh) 2009-10-07
JP2010513240A (ja) 2010-04-30
CN101553483B (zh) 2013-04-17
WO2008071587A2 (en) 2008-06-19
WO2008071587A3 (en) 2008-07-31
AR064221A1 (es) 2009-03-18
EP2089384A2 (en) 2009-08-19
CA2671478C (en) 2015-02-17
US7998969B2 (en) 2011-08-16
EP2089384B1 (en) 2015-08-05
TW200833681A (en) 2008-08-16

Similar Documents

Publication Publication Date Title
PE20081509A1 (es) Inhibidores no nucleosidos de transcriptasa inversa
TR200701870T1 (tr) İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20081448A1 (es) Inhibidores de transcriptasa inversa no nucleosidicos
ATE496043T1 (de) 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
AR047538A1 (es) Piridazinonas como antagonistas de las integrinas alfa4
PE20040592A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
AR054369A1 (es) Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa
ES2564782T3 (es) Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos
PE20070359A1 (es) Inhibidores de pirimidinilpirazol de aurora quinasas
CY1111911T1 (el) Ενωσεις πυριδο (2,3-d) πυριμιδινονης και χρηση αυτων ως αναστολεων ρι3
CO6140060A2 (es) Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5
PE20081059A1 (es) Derivados de pirimidinas como inhibidores de la actividad de la tirosina quinasa de bruton (btk)
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
MX2009010503A (es) Compuestos heterociclicos antiviricos.
PE20090067A1 (es) Inhibidores no nucleosidos de transcriptasa inversa
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
PE20090984A1 (es) Inhibidores de peptido desformilasa
NO20090405L (no) Ikke-nukleoside revers transcriptase inhibitorer
PE20120937A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE20030100A1 (es) Compuestos de n-formil-hidroxilamina
BRPI0510335A (pt) composto heterocìclico
PE20070640A1 (es) Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38

Legal Events

Date Code Title Description
FA Abandonment or withdrawal